Examples of different stimuli for all subtasks of the task. by Marcel F. Hinss (14675457)

Subjects:

Summary of demographics: Left: Distribution of age; Right: Distribution of handedness as assessed by the EDI [40]. by Marcel F. Hinss (14675457)

Subjects:

Heatmap of selected compounds which showed significant changes in concentration in potato tissues in response to ‘<i>Candidatus</i> Liberibacter solanacearum’ (Lso) infection (padj... by Margaret A. Carpenter (6104180)

Table 1_Centella asiatica enhances diabetic wound healing by decreasing macrophage-driven inflammation via the AKT/MAPK/NF-κB pathway.xlsx by Fugang Xiao (22152127)

Comparative death probabilities of tumor-bearing mice across weeks of assessment. by Robert Botelho (20308297)

Subjects:

Study timeline and methodological overview. by Robert Botelho (20308297)

Subjects:

Longitudinal assessment of animal weights and tumor metrics. by Robert Botelho (20308297)

Subjects:

Results of Analysis of Co-variance (ANCOVA) for change in parameter predicted by treatment group with pre-treatment value as a covariate. * p < 0.05; ** p < 0.01. by Lijuan Liu (136685)

Subjects:

Spatial exploration patterns of non-tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). by Robert Botelho (20308297)

Subjects:

Spatial exploration patterns of tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). by Robert Botelho (20308297)

Subjects:

High-affinity choline Uptake (HACU) in the Cortex, Striatum, and Hippocampus of non-tumor and tumor-bearing mice. by Robert Botelho (20308297)

Subjects:

MWM training data. by Robert Botelho (20308297)

Subjects:

Frequency of proestrus in non-tumor and tumor-bearing female mice. by Robert Botelho (20308297)

Subjects:

Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each... by Marsel Ganeyev (21453399)

Subjects:

Quantification of bacterial adhesion revealed a significant decrease in the adhesion of <i>S. aureus</i>, <i>S. epidermidis</i>, and <i>P. aeruginosa</i> on blotted corneas of mice treated with 0.5% bupivacaine (BUP) combined with topical (TOP) application, following subconjunctival injection (SCI) of CGRP, 24 hours before the final BUP treatment (day 14) and again one hour prior to the final bupivacaine injection on day 15. by Ananya Datta (19932144)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Comparison of serum VEGF-A165 concentrations pre-bevacizumab administration in patients with increased VEGF-A post-bevacizumab administration and those with decreased VEGF-A. by Masashi Okawa (8951294)

Subjects: